JPS531190B2
(pl)
|
1974-02-22 |
1978-01-17 |
|
|
US4158059A
(en)
|
1976-05-24 |
1979-06-12 |
Akzona Incorporated |
Tension reducing 2,3,4,4a,9,136-hexahydro-dibenz[1,2;5,6]cyclohepta[3,4-c]py
|
NL7605526A
(nl)
|
1976-05-24 |
1977-11-28 |
Akzo Nv |
Nieuwe tetracyclische derivaten.
|
JPS61502751A
(ja)
*
|
1984-07-23 |
1986-11-27 |
シエリング,コ−ポレ−シヨン |
アザタジンの経度デリバリ−
|
US5474783A
(en)
|
1988-03-04 |
1995-12-12 |
Noven Pharmaceuticals, Inc. |
Solubility parameter based drug delivery system and method for altering drug saturation concentration
|
US5656286A
(en)
|
1988-03-04 |
1997-08-12 |
Noven Pharmaceuticals, Inc. |
Solubility parameter based drug delivery system and method for altering drug saturation concentration
|
US5446070A
(en)
|
1991-02-27 |
1995-08-29 |
Nover Pharmaceuticals, Inc. |
Compositions and methods for topical administration of pharmaceutically active agents
|
DE69009540T2
(de)
|
1989-03-15 |
1994-09-29 |
Nitto Denko Corp |
Arzneimittel enthaltendes Heftpflaster.
|
DE3937271A1
(de)
|
1989-11-09 |
1991-05-16 |
Boehringer Ingelheim Kg |
Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
|
EP0569096A1
(en)
|
1992-05-08 |
1993-11-10 |
Akzo Nobel N.V. |
Depot preparation
|
PL180465B1
(pl)
|
1994-03-02 |
2001-02-28 |
Akzo Nobel Nv |
Kompozycja farmaceutyczna zawierajaca trans-5-chloro-2-metylo-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pirol PL PL PL
|
JP3274579B2
(ja)
|
1995-01-12 |
2002-04-15 |
住友製薬株式会社 |
脳血管障害に伴う精神症候治療剤
|
KR100213465B1
(ko)
|
1996-11-01 |
1999-08-02 |
최좌진 |
케토프로펜 패취 조성물
|
KR20010012985A
(ko)
|
1997-05-26 |
2001-02-26 |
에프.지.엠. 헤르만스 |
방향족 술폰산의 염
|
US7150881B2
(en)
|
1997-06-26 |
2006-12-19 |
Mylan Technologies, Inc. |
Adhesive mixture for transdermal delivery of highly plasticizing drugs
|
GB9714650D0
(en)
|
1997-07-11 |
1997-09-17 |
Strakan Ltd |
Block copolymer
|
WO1999032108A1
(en)
|
1997-12-19 |
1999-07-01 |
Akzo Nobel N.V. |
Org-5222 in the treatment of depression
|
DE19814083C2
(de)
|
1998-03-30 |
2002-02-07 |
Lohmann Therapie Syst Lts |
Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
|
AU748591B2
(en)
|
1998-07-29 |
2002-06-06 |
Teijin Limited |
Pressure-sensitive adhesive composition and moisture-permeable pressure-sensitive adhesive tape, pressure-sensitive adhesive drug composition, and pressure-sensitive adhesive tape preparation each containing the composition
|
US20040142024A1
(en)
|
1999-07-27 |
2004-07-22 |
Hisamitsu Pharmaceutical Co., Inc. |
Patch formulation for external use
|
US20020004065A1
(en)
|
2000-01-20 |
2002-01-10 |
David Kanios |
Compositions and methods to effect the release profile in the transdermal administration of active agents
|
BRPI0116659B8
(pt)
|
2000-11-06 |
2021-05-25 |
Samyang Biopharmaceuticals |
composição para uso em sistema de distribuição transdérmica de droga e sistema de distribuição transdérmica de droga
|
WO2002053140A2
(en)
|
2001-01-02 |
2002-07-11 |
Pharmacia & Upjohn Company |
New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
|
EP1366762B1
(en)
|
2001-03-07 |
2015-12-30 |
Hisamitsu Pharmaceutical Co., Inc. |
Adhesive patch
|
EP1404342A1
(en)
|
2001-04-26 |
2004-04-07 |
Ortho-Mcneil Pharmaceutical, Inc. |
Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
|
GB0119012D0
(en)
|
2001-08-03 |
2001-09-26 |
Strakan Group Plc |
Transdermal delivery of drugs
|
JP4323138B2
(ja)
|
2002-06-05 |
2009-09-02 |
日東電工株式会社 |
経皮吸収型製剤およびその製造方法
|
EP1551393A4
(en)
|
2002-07-30 |
2010-06-16 |
Peter Migaly |
COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
|
JP4642467B2
(ja)
*
|
2002-08-20 |
2011-03-02 |
ユーロ−セルティーク エス.エイ. |
活性剤及び塩並びに副作用物質の遊離塩基形を含む経皮剤形
|
AU2003268376A1
(en)
|
2002-08-30 |
2004-11-26 |
Watson Pharmaceuticals, Inc. |
Transdermal delivery systems and methods
|
WO2004039322A2
(en)
|
2002-10-29 |
2004-05-13 |
Miicro, Inc. |
Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
|
GB0302662D0
(en)
|
2003-02-05 |
2003-03-12 |
Strakan Ltd |
Transdermal granisetron
|
GB0306604D0
(en)
|
2003-03-21 |
2003-04-30 |
Curidium Ltd |
Second medical use
|
RU2005135454A
(ru)
|
2003-05-16 |
2006-06-27 |
Пфайзер Продактс Инк. (Us) |
Терапевтические комбинации атипичных нейролептиков с модуляторами гамк и/или противосудорожными препаратами
|
TWI327915B
(en)
|
2003-06-12 |
2010-08-01 |
Organon Nv |
Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight
|
US20080020028A1
(en)
*
|
2003-08-20 |
2008-01-24 |
Euro-Celtique S.A. |
Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
|
JP2007508297A
(ja)
|
2003-10-10 |
2007-04-05 |
オリックス |
経皮の高分子量化合物及び低分子量化合物
|
CA2542778C
(en)
|
2003-10-28 |
2012-05-29 |
Noven Pharmaceuticals, Inc. |
Transdermal drug delivery composition
|
EP1684734A2
(en)
|
2003-11-18 |
2006-08-02 |
3M Innovative Properties Company |
Olanzapine containing transdermal drug delivery compositions
|
WO2005053796A1
(en)
|
2003-12-02 |
2005-06-16 |
B & B Beheer Nv |
Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
|
EP1547650A1
(en)
|
2003-12-02 |
2005-06-29 |
B & B Beheer NV |
Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
EP1576985A1
(en)
|
2004-03-18 |
2005-09-21 |
B&B Beheer NV |
Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
US7884096B2
(en)
|
2003-12-02 |
2011-02-08 |
Pharmaneuroboost N.V. |
Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
CA2549638A1
(en)
|
2003-12-23 |
2005-07-14 |
Pfizer Products Inc. |
Therapeutic combination for cognition enhancement and psychotic disorders
|
BRPI0507250A
(pt)
|
2004-01-29 |
2007-06-26 |
Pfizer Prod Inc |
combinações para tratar desordens do snc
|
AU2005215257A1
(en)
|
2004-02-13 |
2005-09-01 |
Pfizer Products Inc. |
Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
|
US7650848B2
(en)
|
2004-02-17 |
2010-01-26 |
University Of Florida Research Foundation, Inc. |
Surface topographies for non-toxic bioadhesion control
|
CA2556380A1
(en)
|
2004-03-02 |
2005-09-15 |
Pharmacia Corporation |
Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
|
GB0405200D0
(en)
|
2004-03-08 |
2004-04-21 |
Pfizer Ltd |
Combinations comprising alpha-2-delta ligands
|
US9205062B2
(en)
|
2004-03-09 |
2015-12-08 |
Mylan Pharmaceuticals, Inc. |
Transdermal systems containing multilayer adhesive matrices to modify drug delivery
|
JP4961207B2
(ja)
|
2004-04-21 |
2012-06-27 |
久光製薬株式会社 |
粘着基剤中の吸収促進剤の含有率を高めた外用貼付剤
|
KR20070014184A
(ko)
|
2004-04-22 |
2007-01-31 |
베링거 인겔하임 인터내셔날 게엠베하 |
성기능 장애 치료용 신규 약제학적 조성물 ⅱ
|
JP2007537232A
(ja)
|
2004-05-11 |
2007-12-20 |
ファイザー・プロダクツ・インク |
非定型抗精神病薬と5−ht1b受容体拮抗薬の組合せ
|
WO2006000222A2
(en)
|
2004-06-24 |
2006-01-05 |
H. Lundbeck A/S |
The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
|
US20060019969A1
(en)
|
2004-07-24 |
2006-01-26 |
Laboratorios Dr. Esteve S.A. |
Use of compounds active on the sigma receptor for the treatment of allodynia
|
ITMI20041628A1
(it)
|
2004-08-06 |
2004-11-06 |
Bouty S P A |
Sistema terapeutico a rilascio controllato per uso topico transdermico
|
GB0417702D0
(en)
|
2004-08-09 |
2004-09-08 |
Merck Sharp & Dohme |
New uses
|
US20060039869A1
(en)
*
|
2004-08-17 |
2006-02-23 |
Daniel Wermeling |
Intranasal delivery of antipsychotic drugs
|
MX2007004315A
(es)
|
2004-10-08 |
2008-03-11 |
Noven Pharma |
Dispositivo para suministro transdermico de farmaco que incluye un respaldo oclusivo.
|
WO2006041911A2
(en)
|
2004-10-08 |
2006-04-20 |
Noven Pharmaceuticals, Inc. |
Device transdermal administration of drugs including acrylic polymers
|
RU2403039C2
(ru)
|
2004-10-15 |
2010-11-10 |
H.B.Opганон |
Лечение биполярных расстройств и сопутствующих симптомов
|
ATE413166T1
(de)
|
2004-11-22 |
2008-11-15 |
Hisamitsu Pharmaceutical Co |
Transdermales pflaster enthaltend einen schmelzpunktsenkenden hilfsstoff
|
US20060150989A1
(en)
|
2005-01-12 |
2006-07-13 |
Peter Migaly |
Method of diagnosing, treating and educating individuals with and/or about depression
|
JP2008528532A
(ja)
|
2005-01-28 |
2008-07-31 |
シュヴァルツ・ファーマ・アーゲー |
統合失調症のアドオン治療用spm927
|
JP5084496B2
(ja)
|
2005-02-04 |
2012-11-28 |
久光製薬株式会社 |
経皮吸収貼付剤
|
RU2007132865A
(ru)
|
2005-03-01 |
2009-03-10 |
Пфайзер Лимитед (GB) |
Применение ингибиторов pde7 для лечения невропатической боли
|
WO2006096439A2
(en)
|
2005-03-04 |
2006-09-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
|
GB0506139D0
(en)
*
|
2005-03-24 |
2005-05-04 |
Transphase Ltd |
A transdermal topical composition and its uses
|
US7872147B2
(en)
|
2005-04-07 |
2011-01-18 |
N. V. Organon |
Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
|
JP2008534657A
(ja)
|
2005-04-07 |
2008-08-28 |
ナームローゼ・フエンノートチヤツプ・オルガノン |
トランス−5−クロロ−2−メチル−2,3,3a,12b−テトラヒドロ−1H−ジベンズ[2,3:6,7]−オキセピノ[4,5−c]ピロールの調製のための中間体化合物
|
KR101422843B1
(ko)
|
2005-04-07 |
2014-07-24 |
머크 샤프 앤 도메 비.브이. |
아세나핀 말레에이트의 결정형
|
US7741358B2
(en)
|
2005-04-14 |
2010-06-22 |
N.V. Organon |
Crystal form of asenapine maleate
|
CN101198869A
(zh)
|
2005-04-27 |
2008-06-11 |
株式会社Umn制药 |
胰腺炎的预防及治疗剂
|
CA2548864C
(en)
|
2005-06-06 |
2012-12-11 |
Nitto Denko Corporation |
Percutaneous absorption-type pharmaceutical preparation
|
DE602006003813D1
(de)
|
2005-06-06 |
2009-01-08 |
Fujimoto Co Ltd |
Pharmazeutische Zusammensetzung zur perkutane Absorption unter Verwendung von einem Metalchlorid, vorzugsweise Natriumchlorid, zur Vorbeugung von Kohäsionsschwäche
|
JP5000932B2
(ja)
|
2005-06-21 |
2012-08-15 |
日東電工株式会社 |
ニコチン含有経皮吸収製剤
|
US20070015763A1
(en)
|
2005-07-12 |
2007-01-18 |
Pfizer Inc |
Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist
|
WO2007017750A1
(en)
|
2005-08-08 |
2007-02-15 |
Pfizer Products Inc. |
Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane
|
DE102005050431A1
(de)
|
2005-10-21 |
2007-04-26 |
Lts Lohmann Therapie-Systeme Ag |
Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
|
WO2007046554A1
(ja)
|
2005-10-21 |
2007-04-26 |
Sumitomo Chemical Company, Limited |
ジベンゾオキセピノピロール化合物の製造方法、その中間体及び該中間体の製造方法
|
US7888422B2
(en)
|
2005-11-09 |
2011-02-15 |
Mylan Technologies Inc. |
Long-wearing removable pressure sensitive adhesive
|
TWI389709B
(zh)
*
|
2005-12-01 |
2013-03-21 |
Novartis Ag |
經皮治療系統
|
JP5037831B2
(ja)
|
2006-02-15 |
2012-10-03 |
久光製薬株式会社 |
凝集力向上及び徐放化の外用貼付剤
|
WO2007110878A1
(en)
|
2006-03-27 |
2007-10-04 |
Panacea Biotec Ltd |
Sustained release pharmaceutical composition on the basis of a release system comprising an acid-soluble polymer and a ph-dependent polymer.
|
US20070259952A1
(en)
|
2006-05-02 |
2007-11-08 |
H. Lundbeck A/S |
Uses of escitalopram
|
TW200812993A
(en)
|
2006-05-02 |
2008-03-16 |
Lundbeck & Co As H |
New uses of escitalopram
|
WO2007137224A2
(en)
|
2006-05-22 |
2007-11-29 |
Vanda Pharmaceuticals, Inc. |
Method of treatment
|
BRPI0713104A2
(pt)
|
2006-06-09 |
2012-10-16 |
Dainippon Sumitomo Pharma Co |
preparação de fita.
|
TW200817414A
(en)
|
2006-07-05 |
2008-04-16 |
Organon Nv |
Process for the preparation of asenapine and intermediate products used in said process
|
US7750167B2
(en)
|
2006-07-05 |
2010-07-06 |
N.V. Organon |
Process for the preparation of asenapine and intermediate products used in said process
|
KR20090029299A
(ko)
|
2006-07-14 |
2009-03-20 |
화이자 프로덕츠 인코포레이티드 |
(7s)-7-[(5-플루오로-2-메틸-벤질)옥시]-2-[(2r)-2-메틸피페라진-1-일]-6,7-다이하이드로-5h-사이클로펜타[b]피리딘의 타르트레이트 염
|
US20080045512A1
(en)
|
2006-08-09 |
2008-02-21 |
Pfizer Inc. |
Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
|
CL2007002891A1
(es)
|
2006-10-06 |
2008-04-18 |
Organon Nv |
Trans-5-cloro-2-metil-2,3,3a,12b-tetrahidro-1h-dibenz-[2,3:6,7]oxepino[4,5-c]pirrol 50% amorfo en base al peso total del compuesto; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de un trastorno seleccionado entre e
|
DE102006050558B4
(de)
*
|
2006-10-26 |
2009-03-26 |
Lts Lohmann Therapie-Systeme Ag |
Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
|
KR20090086565A
(ko)
|
2006-12-01 |
2009-08-13 |
닛토덴코 가부시키가이샤 |
안정화된 도네페질 함유 접착 제제
|
US20080131490A1
(en)
|
2006-12-01 |
2008-06-05 |
Akinori Hanatani |
Stabilized donepezil-containing patch preparation
|
CN101563312A
(zh)
|
2006-12-22 |
2009-10-21 |
住友化学株式会社 |
阿塞那平合成中间体的制备方法
|
US7875729B2
(en)
|
2007-01-05 |
2011-01-25 |
Synthon Bv |
Process for making asenapine
|
MY154869A
(en)
|
2007-01-16 |
2015-08-14 |
Ipintl Llc |
Composition for treating metabolic syndrome
|
US20080226698A1
(en)
|
2007-03-16 |
2008-09-18 |
Mylan Technologies, Inc. |
Amorphous drug transdermal systems, manufacturing methods, and stabilization
|
FR2913882B1
(fr)
|
2007-03-20 |
2009-05-01 |
Oreal |
Utilisation pour la coloration des fibres keratiniques d'une composition comprenant un compose halochromique et/ou le colorant correspondant a ce compose
|
WO2008141438A1
(en)
|
2007-05-17 |
2008-11-27 |
Sunnybrook Health Sciences Centre |
Gabaergic modulators for treating airway conditions
|
EP2170399A1
(en)
|
2007-06-05 |
2010-04-07 |
Synthon B.V. |
Intranasal administration of asenapine and pharmaceutical compositions therefor
|
WO2009000890A2
(en)
|
2007-06-27 |
2008-12-31 |
N.V. Organon |
Medication container
|
JP5245428B2
(ja)
|
2007-07-06 |
2013-07-24 |
住友化学株式会社 |
トランス−ジベンゾオキセノピロール化合物の製造方法およびその中間体
|
US20100178323A1
(en)
|
2007-07-10 |
2010-07-15 |
Agis Kydonieus |
Dermal Delivery Device
|
JP5224163B2
(ja)
|
2007-07-24 |
2013-07-03 |
コスメディ製薬株式会社 |
経皮吸収テープ製剤
|
WO2009017453A1
(en)
|
2007-07-30 |
2009-02-05 |
Astrazeneca Ab |
New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
|
WO2009017836A1
(en)
|
2007-08-01 |
2009-02-05 |
Medivation Neurology, Inc. |
Methods and compositions for treating schizophrenia using antipsychotic combination therapy
|
US20090209608A1
(en)
|
2007-08-29 |
2009-08-20 |
Protia, Llc |
Deuterium-enriched asenapine
|
WO2009036100A2
(en)
|
2007-09-10 |
2009-03-19 |
Vanda Pharmaceuticals, Inc. |
Prediction of qt prolongation based on snp genotype
|
CA2699786C
(en)
|
2007-09-10 |
2019-08-13 |
Vanda Pharmaceuticals, Inc. |
Antipsychotic treatment based on snp genotype
|
WO2009035473A2
(en)
|
2007-09-13 |
2009-03-19 |
Sanfilippo Louis C |
Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
|
EP2254577A1
(en)
|
2007-12-26 |
2010-12-01 |
Eisai R&D Management Co., Ltd. |
Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
|
MX2010007404A
(es)
|
2008-01-04 |
2010-10-05 |
Organon Nv |
Procedimiento para la preparacion de asenapina y productos intermediarios utilizados en dicho procedimiento.
|
GB2456183A
(en)
|
2008-01-04 |
2009-07-08 |
Gw Pharma Ltd |
Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
|
US8529441B2
(en)
*
|
2008-02-12 |
2013-09-10 |
Innurvation, Inc. |
Ingestible endoscopic optical scanning device
|
WO2009102962A2
(en)
|
2008-02-13 |
2009-08-20 |
Targacept, Inc. |
Combination of alpha 7 nicotinic agonists and antipsychotics
|
US8580281B2
(en)
|
2008-02-27 |
2013-11-12 |
Hisamitsu Pharmaceutical Co., Inc. |
Medicated patch
|
WO2009121031A1
(en)
|
2008-03-27 |
2009-10-01 |
Vascular Biosciences, Inc. |
Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
|
JP5301190B2
(ja)
|
2008-03-31 |
2013-09-25 |
積水メディカル株式会社 |
貼付剤
|
WO2009135091A1
(en)
|
2008-04-30 |
2009-11-05 |
Medivation Technologies, Inc. |
Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
|
MX2010012989A
(es)
|
2008-05-30 |
2011-04-27 |
Mylan Inc |
Sistema de suministro de farmaco transdermico estabilizado.
|
EP2299983A4
(en)
|
2008-07-24 |
2012-10-10 |
Handa Pharmaceuticals Llc |
ATYPICAL ANTIPSYCHOTIC FORMULATION STABILIZED
|
WO2010020642A1
(en)
|
2008-08-20 |
2010-02-25 |
Brainco Biopharma, S.L. |
Stxbp1 as psychiatric biomarker in murine model system and their uses
|
EP2337564A1
(en)
|
2008-09-04 |
2011-06-29 |
NeuroSearch A/S |
A method for combating adverse effects arising from antipsychotic treatment
|
WO2010060742A1
(en)
|
2008-11-03 |
2010-06-03 |
Solvay Pharmaceuticals B.V. |
Combination of bifeprunox and an antipsychotic drug with d2/5-ht2a receptor antagonistic activity for treating cns disorders
|
WO2010073326A1
(ja)
|
2008-12-24 |
2010-07-01 |
ニチバン株式会社 |
経皮吸収型製剤
|
WO2010080757A2
(en)
|
2009-01-07 |
2010-07-15 |
Astrazeneca Ab |
Combinations with an alpha-4beta-2 nicotinic agonist
|
CA2750028C
(en)
|
2009-01-20 |
2019-05-07 |
Guochuan Emil Tsai |
Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
|
WO2010105093A2
(en)
|
2009-03-12 |
2010-09-16 |
Delpor, Inc. |
Implantable device for long-term delivery of drugs
|
EP2408493A1
(en)
|
2009-03-20 |
2012-01-25 |
Antares Pharma, Inc. |
Hazardous agent injection system
|
WO2010110914A2
(en)
|
2009-03-27 |
2010-09-30 |
Zirus, Inc. |
Mammalian genes involved in infection
|
EP2236157A1
(en)
|
2009-03-30 |
2010-10-06 |
PharmaNeuroBoost N.V. |
Pipamperone and a second agent in treating mood and anxiety disorders
|
CA2757144A1
(en)
|
2009-03-30 |
2010-10-07 |
Pharmaneuroboost N.V. |
Low dose pipamperone in treating mood disorders
|
EP2236138A1
(en)
|
2009-03-30 |
2010-10-06 |
PharmaNeuroBoost N.V. |
Low dose pipamperone in treating mood and anxiety disorders
|
WO2010119455A2
(en)
|
2009-04-15 |
2010-10-21 |
Sun Pharma Advanced Research Company Ltd. |
An injectable sustained release pharmaceutical composition
|
CA2759481A1
(en)
|
2009-04-21 |
2010-10-28 |
Sanomune Inc. |
Tissue kallikrein for the treatment of schizophrenia and bipolar disorder
|
TWI471127B
(zh)
|
2009-04-29 |
2015-02-01 |
Intervet Int Bv |
供人類使用之口服崩解錠劑的製備方法、所製得之口服崩解錠劑、以及含有該口服崩解錠劑的包裝物
|
US8512742B2
(en)
|
2009-05-01 |
2013-08-20 |
Hisamitsu Pharmaceutical Co., Inc. |
Transdermal preparation
|
WO2010127674A1
(en)
*
|
2009-05-06 |
2010-11-11 |
Sunin K/S |
Transdermal compositions of asenapine for the treatment of psychiatric disorders
|
KR101435296B1
(ko)
|
2009-06-24 |
2014-08-27 |
머크 샤프 앤 도메 비.브이. |
아세나핀을 함유하는 주사가능한 제제 및 그를 사용한 치료 방법
|
US20110306596A1
(en)
|
2009-07-27 |
2011-12-15 |
Auspex Pharmaceuticals, Inc. |
Benzazepine inhibitors of gamma-secretase
|
TW201118102A
(en)
|
2009-07-29 |
2011-06-01 |
Organon Nv |
Hydroxyasenapine compounds, derivatives thereof and pharmaceutical compositions comprising same
|
WO2011026060A2
(en)
|
2009-08-31 |
2011-03-03 |
Schneider Eric B |
Treatment and prevention of secondary injury after trauma or damage to the central nervous system
|
US9180191B2
(en)
|
2009-10-16 |
2015-11-10 |
University Of South Florida |
Treatment of suicidal ideation or behavior using inhibitors of nicotinic acetylcholine receptors
|
US20110262442A1
(en)
|
2009-11-06 |
2011-10-27 |
Adenios, Inc. |
Compositions for treating cns disorders
|
CA2784826A1
(en)
|
2009-12-18 |
2011-06-23 |
Exodos Life Sciences Limited Partnership |
Methods and compositions for stable liquid drug formulations
|
WO2011087755A2
(en)
|
2009-12-22 |
2011-07-21 |
Pondera Biotechnologies, LLC |
Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
|
AR079814A1
(es)
|
2009-12-31 |
2012-02-22 |
Otsuka Pharma Co Ltd |
Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
|
AU2010339689B2
(en)
|
2010-01-07 |
2015-02-19 |
Alkermes Pharma Ireland Limited |
Quaternary ammonium salt prodrugs
|
WO2011085188A1
(en)
|
2010-01-07 |
2011-07-14 |
Eurand, Inc. |
Pharmaceutical compositions comprising anti-psychotic drugs
|
WO2011084851A1
(en)
|
2010-01-07 |
2011-07-14 |
Alkermes, Inc. |
Asenapine produrugs
|
ITMI20100260A1
(it)
|
2010-02-19 |
2011-08-20 |
Giulio Scigliano |
Composizione farmaceutica contenente un farmaco per ridurre gli effetti collaterali dei farmaci antipsicotici
|
JP5615899B2
(ja)
|
2010-02-24 |
2014-10-29 |
久光製薬株式会社 |
経皮吸収製剤
|
US9370495B2
(en)
|
2010-02-24 |
2016-06-21 |
Hisamitsu Pharmaceutical Co., Inc. |
Adhesive patch
|
WO2011107855A2
(en)
|
2010-03-04 |
2011-09-09 |
Torrent Pharmaceuticals Limited |
Sustained release oral liquid suspension dosage form
|
US20130245253A1
(en)
|
2010-03-26 |
2013-09-19 |
Department Of Veterans Affairs |
Conjugated Neuroactive Steroid Compositions And Methods Of Use
|
WO2011136283A1
(ja)
|
2010-04-28 |
2011-11-03 |
久光製薬株式会社 |
皮膚刺激抑制剤及び経皮吸収製剤
|
WO2011143755A1
(en)
|
2010-05-21 |
2011-11-24 |
Serdar Dursun |
Compositions and methods of treating schizophrenia
|
CN101851242B
(zh)
|
2010-05-25 |
2013-07-24 |
上海皓元生物医药科技有限公司 |
阿塞那平中间体的制备方法
|
US8779161B2
(en)
|
2010-06-18 |
2014-07-15 |
Dr. Reddy's Laboratories Limited |
Asenapine maleate
|
CA2805542C
(en)
|
2010-07-29 |
2017-12-12 |
Laboratorios Lesvi, S.L. |
Novel process for the preparation of asenapine
|
WO2012037457A1
(en)
|
2010-09-16 |
2012-03-22 |
Cornell University |
Use of adenosine receptor signaling to modulate permeability of blood-brain barrier
|
WO2012038975A2
(en)
|
2010-09-22 |
2012-03-29 |
Msn Laboratories Limited |
Process for the preparation of (3ars,12brs)-5-chloro-2-methyl-2,3,3a12b-tetrahydro-1hdibenzo[2,3:6,7] oxepino [4,5-c]pyrrole maleate and it's pharmaceutical composition thereof
|
US20130274466A1
(en)
|
2010-09-27 |
2013-10-17 |
Alphora Research Inc. |
Process for the preparation of tetracyclic derivatives and intermediate products used in the process
|
WO2012065102A2
(en)
|
2010-11-12 |
2012-05-18 |
Promentis Pharmaceuticals, Inc. |
S-t-butyl protected cysteine di-peptide analogs and related compounds
|
US20120122793A1
(en)
|
2010-11-12 |
2012-05-17 |
Promentis Pharmaceuticals, Inc. |
S-Protected Cysteine Analogs and Related Compounds
|
WO2012066565A2
(en)
|
2010-11-16 |
2012-05-24 |
Cadila Healthcare Limited |
Asenapine maleate amorphous and crystalline form and process for preparation thereof
|
DK2640389T3
(en)
|
2010-11-17 |
2015-03-09 |
Hexal Ag |
Transdermal therapeutic system comprising buprenorphine
|
WO2012070043A1
(en)
|
2010-11-26 |
2012-05-31 |
Ramot At Tel-Aviv University Ltd. |
Method and composition for weight-gain management
|
WO2012070034A1
(en)
|
2010-11-26 |
2012-05-31 |
University Of The Witwatersrand, Johannesburg |
A drug delivery device
|
EP2468750A1
(en)
|
2010-12-13 |
2012-06-27 |
Chemo Ibérica, S.A. |
Polymorphic forms of asenapine maleate and processes for their preparation
|
CA2822447C
(en)
|
2010-12-23 |
2018-05-01 |
Alkermes Pharma Ireland Limited |
Multi-api loading prodrugs
|
EP2468751B1
(en)
|
2010-12-24 |
2016-03-16 |
Medichem, S.A. |
Processes for the preparation of 5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
WO2012114325A1
(en)
|
2011-02-23 |
2012-08-30 |
Mapi Pharma Limited |
Polymorphs of asenapine maleate
|
WO2012123325A1
(en)
|
2011-03-11 |
2012-09-20 |
Medichem S.A. |
NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
|
CN103501770B
(zh)
|
2011-04-18 |
2015-04-29 |
久光制药株式会社 |
贴附剂的制造方法及贴附剂
|
ITMI20110734A1
(it)
|
2011-05-02 |
2012-11-03 |
Olon Spa |
Sali cristallini di asenapina
|
EP2524920A1
(en)
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel Crystalline Asenapine Hydrochloride Salt Forms
|
EP2524919A1
(en)
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
|
EP2524921A1
(en)
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel Crystalline Salts of Asenapine
|
JP6014656B2
(ja)
|
2011-05-18 |
2016-10-25 |
ラビラトリオス レスビ エス エレ |
化合物の多形体
|
EP2709615A1
(en)
|
2011-05-18 |
2014-03-26 |
Laboratorios Lesvi, S.L. |
Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
|
DE102011076653A1
(de)
|
2011-05-27 |
2012-11-29 |
Acino Ag |
Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
|
US9526718B2
(en)
|
2011-06-28 |
2016-12-27 |
Vivozon, Inc. |
Combination of effective substances causing synergistic effects of multiple targeting and use thereof
|
JP2014522837A
(ja)
|
2011-06-29 |
2014-09-08 |
大塚製薬株式会社 |
治療用化合物としてのキナゾリン及び関連の使用方法
|
WO2013024492A2
(en)
|
2011-07-01 |
2013-02-21 |
Megafine Pharma (P) Ltd. |
A process for the preparation of asenapine and novel salts thereof
|
WO2013011461A1
(en)
|
2011-07-20 |
2013-01-24 |
Ranbaxy Laboratories Limited |
Process for the preparation of asenapine maleate
|
CA2842106A1
(en)
|
2011-07-28 |
2013-01-31 |
Promentis Pharmaceuticals, Inc. |
Cysteine prodrugs
|
AR082640A1
(es)
*
|
2011-08-25 |
2012-12-19 |
Amarin Technologies S A |
Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
|
WO2013035109A1
(en)
|
2011-09-08 |
2013-03-14 |
Mylan Laboratories Ltd |
Improved process for the preparation of asenapine maleate
|
WO2013040419A1
(en)
|
2011-09-14 |
2013-03-21 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods for treating hyperprolinemia-associated mental disorders
|
WO2013041604A1
(en)
|
2011-09-21 |
2013-03-28 |
Sandoz Ag |
Crystal form of asenapine maleate
|
EP2572703A1
(en)
|
2011-09-21 |
2013-03-27 |
Hexal AG |
Compressed oral dosage form for asenapine maleate
|
CA2853249A1
(en)
|
2011-10-24 |
2013-05-02 |
Endo Pharmaceuticals Solutions Inc. |
Implantable tizanidine compositions and methods of treatment thereof
|
WO2013061247A1
(en)
|
2011-10-24 |
2013-05-02 |
Alembic Pharmaceuticals Limited |
Novel process for the preparation of asenapine
|
US20140350081A1
(en)
|
2011-11-04 |
2014-11-27 |
Purdue Research Foundation |
Insect g-coupled receptors useful as targets for insecticides and compounds and reagents identified using the same
|
US20140336391A1
(en)
|
2011-11-28 |
2014-11-13 |
Ranbaxy Laboratories Limited |
Process for the preparation of asenapine intermediate
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
WO2013114400A2
(en)
|
2012-01-20 |
2013-08-08 |
Rubicon Research Private Limited |
Compressed pharmaceutical compositions of atypical antipsychotics
|
CN103254201B
(zh)
|
2012-02-21 |
2016-04-13 |
四川科伦药物研究有限公司 |
一种阿塞那平的制备方法
|
ES2637341T3
(es)
|
2012-03-14 |
2017-10-11 |
Levicept Ltd. |
Proteína de unión a neurotrofina P75NTR para su utilización terapéutica
|
DE102012205493A1
(de)
|
2012-04-03 |
2013-10-10 |
Acino Ag |
Einen Dopamin-Agonisten enthaltendes transdermales Applikationssystem
|
WO2013158939A1
(en)
|
2012-04-18 |
2013-10-24 |
Hemoshear, Llc |
In vitro model for pathological or physiologic conditions
|
KR20130120648A
(ko)
|
2012-04-26 |
2013-11-05 |
에스에프씨 주식회사 |
벤조사이클로플루오렌계 화합물 및 이를 포함하는 유기전계발광소자
|
WO2013170000A1
(en)
|
2012-05-09 |
2013-11-14 |
The Rockfeller University |
Methods and compositions for activity dependent transcriptome profiling
|
WO2013190481A1
(en)
|
2012-06-21 |
2013-12-27 |
Alembic Pharmaceuticals Limited |
Process for preparing asenapine and salts of intermediates thereof
|
JP6005742B2
(ja)
|
2012-07-26 |
2016-10-12 |
久光製薬株式会社 |
貼付剤
|
US8986677B2
(en)
|
2012-07-30 |
2015-03-24 |
Pop Test Cortisol Llc |
Therapeutic compositions and methods
|
US10137081B2
(en)
|
2012-09-28 |
2018-11-27 |
Delpor, Inc. |
Device and method for sustained release of antipsychotic medications
|
ITMI20121810A1
(it)
|
2012-10-24 |
2014-04-25 |
Chemo Iberica Sa |
Poliformi di maleato di asenapina e processo per la loro preparazione
|
JOP20210047A1
(ar)
|
2012-10-25 |
2017-06-16 |
Otsuka Pharma Co Ltd |
عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
|
US10154988B2
(en)
*
|
2012-11-14 |
2018-12-18 |
The Johns Hopkins University |
Methods and compositions for treating schizophrenia
|
WO2014078377A1
(en)
|
2012-11-14 |
2014-05-22 |
Agenebio, Inc. |
Methods and compositions for treating schizophrenia
|
WO2014080378A1
(en)
|
2012-11-26 |
2014-05-30 |
University Of Cape Town |
Phenothiazine derivatives and their use against tuberculosis
|
JP2014105205A
(ja)
|
2012-11-30 |
2014-06-09 |
Medical Front Co Ltd |
医用貼付剤
|
WO2014090386A1
(en)
|
2012-12-11 |
2014-06-19 |
Alfred E. Tiefenbacher (Gmbh & Co. Kg) |
Orally disintegrating tablet containing asenapine
|
JP6391120B2
(ja)
|
2012-12-20 |
2018-09-19 |
サンフォード−バーンハム メディカル リサーチ インスティテュート |
ニューロテンシン受容体1の小分子アゴニスト
|
CN103893139B
(zh)
|
2012-12-28 |
2018-06-08 |
石药集团中奇制药技术(石家庄)有限公司 |
一种阿塞那平组合物及其制备方法
|
TWI646091B
(zh)
|
2012-12-28 |
2019-01-01 |
日商衛斯克慧特股份有限公司 |
鹽類及晶形
|
JP6359032B2
(ja)
|
2012-12-28 |
2018-07-18 |
ノーヴェン ファーマシューティカルズ インコーポレイテッド |
経皮薬物送達用のマルチポリマー組成物
|
CN103965206A
(zh)
|
2013-01-29 |
2014-08-06 |
北京京卫燕康药物研究所有限公司 |
一种阿色纳品马来酸盐的新晶型及制备方法
|
EP2953678B1
(en)
|
2013-02-06 |
2020-03-25 |
Sillender, Mark |
Therapeutic substance transfer catheter
|
WO2014127786A1
(en)
|
2013-02-22 |
2014-08-28 |
Zentiva, K.S. |
Orally disintegrating pharmaceutical composition comprising asenapine
|
WO2014165136A1
(en)
|
2013-03-12 |
2014-10-09 |
Antares Pharma, Inc. |
Constant volume prefilled syringes and kits thereof
|
WO2014160167A1
(en)
|
2013-03-14 |
2014-10-02 |
Endo Pharmaceuticals Solutions Inc. |
Implantable drug delivery compositions comprising aromatic polyurethanes and methods of treatment thereof
|
WO2014160155A2
(en)
|
2013-03-14 |
2014-10-02 |
Endo Pharmaceuticals Solutions Inc. |
Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof
|
US20140276479A1
(en)
*
|
2013-03-14 |
2014-09-18 |
Noven Pharmaceuticals, Inc. |
Transdermal drug delivery system with overlay
|
US20140271923A1
(en)
|
2013-03-14 |
2014-09-18 |
Christopher Brian Reid |
Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
|
WO2014152965A2
(en)
|
2013-03-14 |
2014-09-25 |
The Children's Hospital Of Philadelphia |
Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets
|
WO2014160026A2
(en)
|
2013-03-14 |
2014-10-02 |
Endo Pharmaceuticals Solutions Inc. |
Implantable drug delivery compositions comprising sugar-based sorption enhancers and methods of treatment thereof
|
US20140274764A1
(en)
|
2013-03-15 |
2014-09-18 |
Pathway Genomics Corporation |
Method and system to predict response to treatments for mental disorders
|
US20140287529A1
(en)
|
2013-03-15 |
2014-09-25 |
Ameritox, Ltd. |
Methods of normalizing measured drug concentrations and testing for potential non-compliance with a drug treatment regimen
|
EP2968248A4
(en)
*
|
2013-03-15 |
2016-08-31 |
Nal Pharmaceutical Group Ltd |
TRANSDERMAL ACTIVE COMPOSITION SYSTEM WITH RIVASTIGMIN
|
AR095259A1
(es)
|
2013-03-15 |
2015-09-30 |
Noven Pharma |
Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
|
MX2015012760A
(es)
|
2013-03-15 |
2016-06-17 |
Als Mountain Llc |
Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma.
|
JP6129632B2
(ja)
|
2013-04-24 |
2017-05-17 |
帝國製薬株式会社 |
貼付剤
|
CN105377245B
(zh)
*
|
2013-06-04 |
2018-07-17 |
Lts勒曼治疗系统股份公司 |
透皮递送系统
|
WO2014197744A1
(en)
|
2013-06-05 |
2014-12-11 |
Synchroneuron, Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
IN2013MU02206A
(pl)
|
2013-06-28 |
2015-06-12 |
Alembic Pharmaceuticals Ltd |
|
WO2015027342A1
(en)
|
2013-08-30 |
2015-03-05 |
Mcmaster University |
Microgel compositions for delivery of substances to the brain
|
CN104447770A
(zh)
|
2013-09-12 |
2015-03-25 |
天津市汉康医药生物技术有限公司 |
阿塞那平化合物
|
CN104447771A
(zh)
|
2013-09-12 |
2015-03-25 |
天津市汉康医药生物技术有限公司 |
一种稳定的马来酸阿塞那平化合物
|
US10098893B2
(en)
|
2013-10-03 |
2018-10-16 |
Northwestern University |
Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457
|
US9757330B2
(en)
|
2013-10-18 |
2017-09-12 |
Industrial Technology Research Institute |
Recipe for in-situ gel, and implant, drug delivery system formed thereby
|
IN2013MU03596A
(pl)
|
2013-11-18 |
2015-07-24 |
Piramal Entpr Ltd |
|
EP3666271A1
(en)
|
2013-12-03 |
2020-06-17 |
Intra-Cellular Therapies, Inc. |
Miscrospheres comprising a plga matrix for medical use
|
EP3076951B1
(en)
|
2013-12-05 |
2020-09-30 |
Celal Albayrak |
Process for the production of drug formulations for oral administration
|
WO2015087927A1
(ja)
*
|
2013-12-12 |
2015-06-18 |
久光製薬株式会社 |
カバー材付き貼付剤及びカバー材付き貼付剤キット
|
CN103772402A
(zh)
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
一种新的阿塞那平马来酸盐粗品精制方法
|
CN103772401A
(zh)
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
11-氯-2,3,3a,12b-四氢-2-甲基-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯-1-酮的一种新精制方法
|
CN103772400A
(zh)
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
反式-5-氯-2,3,3a,12b-四氢-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯的制备方法
|
CN103760280A
(zh)
|
2014-01-10 |
2014-04-30 |
万特制药(海南)有限公司 |
一种用液相色谱法分离测定阿塞那平中间体有关物质的方法
|
WO2015120317A1
(en)
|
2014-02-07 |
2015-08-13 |
Neurocrine Biosciences, Inc. |
Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
|
US20170007537A1
(en)
|
2014-02-18 |
2017-01-12 |
Hetero Research Foundation |
Pharmaceutical compositions of asenapine
|
CN106456662A
(zh)
|
2014-02-24 |
2017-02-22 |
奥利金制药公司 |
口服给药的戊聚糖多硫酸盐的组合物及其使用方法
|
WO2015127556A1
(en)
|
2014-02-28 |
2015-09-03 |
UNIVERSITé LAVAL |
Methods and uses for inducing or facilitating defecation in a patient in need thereof
|
WO2015127558A1
(en)
|
2014-02-28 |
2015-09-03 |
UNIVERSITé LAVAL |
Methods and uses for inducing or facilitating micturition in a patient in need thereof
|
WO2015127557A1
(en)
|
2014-02-28 |
2015-09-03 |
Centre For Addiction And Mental Health |
Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain
|
CN103864802B
(zh)
|
2014-03-31 |
2016-08-17 |
四川科伦药业股份有限公司 |
马来酸阿塞那平的制备方法
|
CN104974168B
(zh)
|
2014-04-02 |
2019-01-04 |
洋浦慧谷医药有限公司 |
阿塞那平的制备方法以及用于制备阿塞那平的中间体
|
CN104974167B
(zh)
|
2014-04-02 |
2019-01-04 |
洋浦慧谷医药有限公司 |
阿塞那平的制备方法以及用于制备阿塞那平的中间体
|
EP3125893B1
(en)
|
2014-04-04 |
2023-09-20 |
Intra-Cellular Therapies, Inc. |
Deuterated heterocycle fused gamma-carbolines as antagonists of 5-ht2a receptors
|
EP3125892A4
(en)
|
2014-04-04 |
2017-12-27 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
CN104000800A
(zh)
|
2014-04-28 |
2014-08-27 |
万特制药(海南)有限公司 |
马来酸阿塞那平口腔速溶膜剂及其制备方法
|
CN106456567A
(zh)
|
2014-05-20 |
2017-02-22 |
Lts勒曼治疗系统股份公司 |
在经皮递送系统中调节活性剂释放的方法
|
CA2948221C
(en)
|
2014-05-20 |
2022-11-22 |
Lts Lohmann Therapie-Systeme Ag |
Transdermal delivery system including an interface mediator
|
US9878138B2
(en)
|
2014-06-03 |
2018-01-30 |
Pop Test Abuse Deterrent Technology Llc |
Drug device configured for wireless communication
|
US10179776B2
(en)
|
2014-06-09 |
2019-01-15 |
Intra-Cellular Therapies, Inc. |
Compounds and methods of use to treat schizophrenia
|
CN104133010B
(zh)
|
2014-07-01 |
2019-11-29 |
北京万全德众医药生物技术有限公司 |
高效液相色谱法分离分析阿西马朵林中间体及光学异构体
|
CN104133012B
(zh)
|
2014-07-02 |
2020-01-07 |
北京万全德众医药生物技术有限公司 |
一种高效液相色谱法测定马来酸阿塞那平消旋体的方法
|
WO2016009064A1
(en)
*
|
2014-07-18 |
2016-01-21 |
Buzzz Pharmaceuticals Limited |
Abuse deterrent opiod/opiod-antagonist transdermal patch
|
CN104098580B
(zh)
|
2014-07-22 |
2016-04-13 |
成都百裕科技制药有限公司 |
一种阿塞那平关键中间体的制备方法
|
MX370376B
(es)
|
2014-07-31 |
2019-12-11 |
Noven Pharma |
Polímeros acrílicos que contienen silicona para composiciones para suministro de fármacos transdérmicos.
|
ES2562684B1
(es)
|
2014-08-04 |
2017-02-06 |
Consejo Superior De Investigaciones Científicas (Csic) |
Método de monitorización de tratamiento antipsicótico
|
WO2016023658A1
(en)
|
2014-08-14 |
2016-02-18 |
Alrise Biosystems Gmbh |
Injectable formulations of asenapine
|
JP2016056142A
(ja)
|
2014-09-11 |
2016-04-21 |
第一三共株式会社 |
Pde10a阻害薬と抗精神病薬の組み合わせ
|
CN104297366A
(zh)
|
2014-09-24 |
2015-01-21 |
万特制药(海南)有限公司 |
马来酸阿塞那平及其杂质的液相分析方法
|
EP3206678B1
(en)
|
2014-10-14 |
2019-12-11 |
Sculpt B.V. |
Body sculpting
|
ES2954860T3
(es)
|
2014-10-24 |
2023-11-27 |
Launx Biomedical Co Ltd |
Uso de azelnidipina en la preparación de una composición medicinal para el tratamiento de cánceres
|
EP3020782B1
(en)
|
2014-11-11 |
2018-08-01 |
SFC Co., Ltd. |
An electroluminescent compound and an electroluminescent device comprising the same
|
WO2016086193A1
(en)
|
2014-11-25 |
2016-06-02 |
Nanocopoeia, Llc |
Amorphous nanoparticles prepared by electrospraying
|
US20170343634A1
(en)
|
2014-12-01 |
2017-11-30 |
The Feinstein Institute For Medical Research |
Use of striatal connectivity patterns for evaluating antipsychotic agents
|
EP3227680A4
(en)
|
2014-12-05 |
2018-05-16 |
Myriad Genetics, Inc. |
Biomarkers for distinguishing mood disorders
|
EP3031458A1
(en)
|
2014-12-09 |
2016-06-15 |
Iproteos S.L. |
Use of 1-[(2-phenylcycloprop-1-yl)carbonyl]-2-[(1,3-thiazolidin-3-yl)carbonyl]perhydroindole in the treatment of schizophrenia-associated cognitive deficits
|
US9656441B2
(en)
*
|
2015-01-08 |
2017-05-23 |
Alfred E. Tiefenbacher ( Gmbh & Co. Kg) |
Transdermal patch
|
WO2016114655A1
(en)
|
2015-01-12 |
2016-07-21 |
Ry Pharma B.V. |
Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
|
EP3251663A1
(en)
|
2015-01-30 |
2017-12-06 |
Toyo Ink Sc Holdings Co., Ltd. |
Adhesive patch
|
WO2016138138A1
(en)
|
2015-02-25 |
2016-09-01 |
The Regents Of The University Of California |
5ht agonists for treating disorders
|
JP6360614B2
(ja)
*
|
2015-03-02 |
2018-07-18 |
久光製薬株式会社 |
貼付剤
|
KR20160107610A
(ko)
|
2015-03-04 |
2016-09-19 |
한국과학기술원 |
대사 질환의 예방 또는 치료용 조성물
|
ITUB20150635A1
(it)
|
2015-04-14 |
2016-10-14 |
Giuseppe Lotito |
Uso di un inibitore dell’aceticolinesterasi e composizioni farmaceutiche contenenti detto inibitore.
|
US10864190B2
(en)
|
2015-04-22 |
2020-12-15 |
CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH |
Combination of an antiandrogen with a vitamin K antagonist or with a gamma-glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
US20190055603A1
(en)
|
2015-04-28 |
2019-02-21 |
Proove Biosciences, Inc. |
System and method for processing genotype information relating to drug metabolism
|
ES2598248B1
(es)
|
2015-06-26 |
2017-12-18 |
Centro De Investigación Biomédica En Red |
Método in vitro y kit para el pronóstico o predicción de la respuesta al tratamiento con agentes antipsicóticos por parte de pacientes que han sufrido un primer episodio psicótico
|
EP3329914A4
(en)
*
|
2015-07-27 |
2019-04-03 |
Hisamitsu Pharmaceutical Co., Inc. |
METHOD FOR MANUFACTURING A STAMPER CONTAINING ASENAPINE
|
EP3329915A4
(en)
*
|
2015-07-27 |
2019-03-27 |
Hisamitsu Pharmaceutical Co., Inc. |
ADHESIVE PATCH CONTAINING ASENAPINE
|
CN105566336A
(zh)
|
2016-01-08 |
2016-05-11 |
万特制药(海南)有限公司 |
一种制备阿塞那平去甲基杂质的新方法
|
CN105693735A
(zh)
|
2016-01-15 |
2016-06-22 |
万特制药(海南)有限公司 |
马来酸阿塞那平一种制备方法
|
WO2017131034A1
(ja)
|
2016-01-28 |
2017-08-03 |
久光製薬株式会社 |
経皮吸収製剤
|
JP6658201B2
(ja)
|
2016-03-28 |
2020-03-04 |
東洋インキScホールディングス株式会社 |
貼付剤
|
KR20160108258A
(ko)
|
2016-06-20 |
2016-09-19 |
한국과학기술원 |
대사 질환의 예방 또는 치료용 조성물
|
CN109789134A
(zh)
|
2016-07-27 |
2019-05-21 |
考里安国际公司 |
与口服递送药代动力学生物等效的透皮递送系统
|
US20180193283A1
(en)
|
2016-12-20 |
2018-07-12 |
Lts Lohmann Therapie-Systeme Ag |
Transdermal therapeutic system containing asenapine
|